Our unique approach.

Our first product candidate, KT 20610, is targeting the gut-brain-ECS axis.

Our cannabinoid based treatment, utilises a unique delivery methodology, that improves bioavailability, and by bypassing the liver, has the potential to reduce adverse effects.

By developing a cannabinoid based treatment, we are able to reduce overall risks and costs throughout our drug development pathway. Our core cannabinoids are already approved drugs, who’s efficacy & safety in multiple areas, is well known.

Our product will have multiple IP protections, many of which are pending or secured.

Our unique product.

We are focused on one development product initially whilst we assess other clinical targets in paediatrics where KT-20610 may be effective as well as looking at other gut-brain-ECS axis related compounds for future development.

Clinically Relevant

Data shows the relevance of gut issues on neurodevelopment are significant, causing behavioural problems, reduced life expectancy and impacting on brain development. Over 50% of children with ASD have gut issues.

Evidence Based

We are combining the scientific excitement around the gut-brain-axis, with significant data already available around the role of the endocannabinoid system in ASD. Our initial research has shown an improvement in gut function and behaviour with KT-20160.

Ground-Breaking Science

The gut-brain axis is one of the most exciting areas of research in ASD. By jointly targeting the gut and the brain we believe we can improve both physical and behavioural issues in ASD (significant issues for those affected).

A unique need.

ASD can be a very significant neurodevelopmental disorder, which can have a major impact on the lives and futures of those with ASD as well as their carers and families.

According to the US CDC, 1 in 36 (or 2.78%) of children in the US have ASD, this has increased from 1 in 54 in 2020. The data published in 2023 shows an increase of over 317% since 2000.

40% of children with ASD are non verbal and 31% have an intellectual disability and premature death rates are three to ten times higher for individuals with ASD.

There are very few effective and parentally acceptable clinical interventions available.